Comparative Pharmacology
Head-to-head clinical analysis: AUVI Q versus EPIPEN JR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUVI Q versus EPIPEN JR.
AUVI-Q vs EPIPEN JR.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine is a direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-adrenergic stimulation increases peripheral vascular resistance, reversing hypotension and improving coronary perfusion. Beta-adrenergic stimulation causes bronchodilation, positive chronotropic and inotropic effects, and vasodilation.
Epinephrine is a direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-adrenergic effects include vasoconstriction, which reduces edema and increases blood pressure. Beta-adrenergic effects include bronchodilation, positive inotropic and chronotropic cardiac effects, and inhibition of histamine release from mast cells.
0.3 mg intramuscularly into anterolateral thigh, repeated every 5-15 minutes as needed.
Epinephrine 0.3 mg intramuscularly in the mid-outer thigh every 5-15 minutes as needed for anaphylaxis.
None Documented
None Documented
The terminal elimination half-life of epinephrine is approximately 2–3 minutes when administered intravenously. After intramuscular injection, the half-life is extended to about 20–30 minutes due to slower absorption, providing a longer duration of therapeutic effect.
Terminal elimination half-life is approximately 2-3 minutes following intravenous administration. Clinically, the short half-life necessitates repeat dosing or continuous infusion for sustained effect. After intramuscular injection, absorption is slower, and the effective half-life is longer due to continued absorption.
Epinephrine is rapidly metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Renal excretion of metabolites accounts for the majority of elimination; less than 5% is excreted unchanged in urine.
Epinephrine is rapidly metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). The metabolites, including metanephrine and vanillylmandelic acid (VMA), are primarily excreted renally. About 85-90% of an administered dose is eliminated in the urine within 24 hours, with less than 5% excreted unchanged. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Adrenergic Agonist
Adrenergic Agonist